Meeting
2020 ASCO Virtual Scientific Program
Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel).
Authors
Sairah Ahmed
The University of Texas MD Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX
Sairah Ahmed , fateeha furqan , Paolo Strati , Jason Westin , Luis Fayad , Frederick B. Hagemeister , Hun Ju Lee , Swaminathan Padmanabhan Iyer , Ranjit Nair , Loretta J. Nastoupil , Simrit Parmar , Maria Alma Rodriguez , Felipe Samaniego , Raphael Steiner , Michael Wang , Chelsea Camille Pinnix , Christopher Flowers , Sandra B. Horowitz , Misha Hawkins , Sattva Swarup Neelapu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Citation
J Clin Oncol 38: 2020 (suppl; abstr 8057)
DOI
10.1200/JCO.2020.38.15_suppl.8057
Abstract #
8057
Poster Bd #
390
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.
First Author: Jason Westin
Poster
2022 ASCO Annual Meeting
Quality-adjusted time without symptoms or toxicities (Q-TWiST) analysis of ZUMA-7, a randomized controlled trial of axicabtagene ciloleucel versus standard of care for second-line large B-cell lymphoma.
First Author: Marie José Kersten
Poster
2022 ASCO Annual Meeting
Trial in progress: A phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 (efineptakin alfa), a long-acting human IL-7, post-tisagenlecleucel in subjects with relapsed/refractory large B-cell lymphoma.
First Author: Armin Ghobadi
Poster
2020 ASCO Virtual Scientific Program
Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).
First Author: Paolo Strati